This project aims to develop a new immunotherapy approach for lung cancer by targeting dendritic cell activation. We are using the Influenza A virus strain PR8 (A/Puerto Rico/8/34) as a viral vector/agent in our in vivo models.
Following a new amplification of our viral stocks (two distinct MOIs: 10 e−3 and 10e−4), we require a full genome sequencing (NGS-Illumina) to:
Confirm the genetic integrity of the 8 viral segments.
Ensure the absence of any low-level bacterial or adventitious contamination.
This quality control is a prerequisite before starting the animal experiments to guarantee the reproducibility and safety of our immunotherapy assays.
